Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Immunologic Research
Published in: Immunologic Research 4/2017

01-08-2017 | Review

Polymorphisms in miRNA genes and their involvement in autoimmune diseases susceptibility

Authors: Andrea Latini, Cinzia Ciccacci, Giuseppe Novelli, Paola Borgiani

Published in: Immunologic Research | Issue 4/2017

Login to get access

Abstract

MicroRNAs (miRNAs) are small non-coding RNA molecules that negatively regulate the expression of multiple protein-encoding genes at the post-transcriptional level. MicroRNAs are involved in different pathways, such as cellular proliferation and differentiation, signal transduction and inflammation, and play crucial roles in the development of several diseases, such as cancer, diabetes, and cardiovascular diseases. They have recently been recognized to play a role also in the pathogenesis of autoimmune diseases. Although the majority of studies are focused on miRNA expression profiles investigation, a growing number of studies have been investigating the role of polymorphisms in miRNA genes in the autoimmune diseases development. Indeed, polymorphisms affecting the miRNA genes can modify the set of targets they regulate or the maturation efficiency. This review is aimed to give an overview about the available studies that have investigated the association of miRNA gene polymorphisms with the susceptibility to various autoimmune diseases and to their clinical phenotypes.
Literature
1.
O’Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol. 2010;10:111–22.PubMedCrossRef
2.
Singh RP, Massachi I, Manickavel S, Singh S, Rao NP, Hasan S, et al. The role of miRNA in inflammation and autoimmunity. Autoimmun Rev. 2013;12:1160–5.PubMedCrossRef
3.
4.
Swarup V, Rajeswari MR. Circulating (cell-free) nucleic acids—a promising, noninvasive tool for early detection of several human diseases. FEBS Lett. 2007;581:795–9.PubMedCrossRef
5.
Iborra M, Bernuzzi F, Invernizzi P, Danese S. MicroRNAs in autoimmunity and inflammatory bowel disease: crucial regulators in immune response. Autoimmun Rev. 2012;11:305–14.PubMedCrossRef
6.
Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009;10:126–39.PubMedCrossRef
7.
8.
Chatzikyriakidou A, Voulgari PV, Georgiou I, Drosos AA. miRNAs and related polymorphisms in rheumatoid arthritis susceptibility. Autoimmun Rev. 2012;11:636–41.PubMedCrossRef
9.
Miao CG, Yang YY, He X, Huang C, Huang Y, Zhang L, et al. The emerging role of microRNAs in the pathogenesis of systemic lupus erythematosus. Cell Signal. 2013;25:1828–36.PubMedCrossRef
10.
Fabian MR, Sonenberg N. The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol. 2012;19:586–93.PubMedCrossRef
11.
Neilson JR, Zheng GX, Burge CB, Sharp PA. Dynamic regulation of miRNA expression in ordered stages of cellular development. Genes Dev. 2007;21:578–89.PubMedPubMedCentralCrossRef
12.
Deng X, Su Y, Wu H, Wu R, Zhang P, Dai Y, et al. The role of microRNAs in autoimmune diseases with skin involvement. Scand J Immunol. 2015;81:153–65.PubMedCrossRef
13.
Pivarcsi A, Ståhle M, Sonkoly E. Genetic polymorphisms altering microRNA activity in psoriasis—a key to solve the puzzle of missing heritability? Exp Dermatol. 2014;23:620–4.PubMedCrossRef
14.
Kim HK, Prokunina-Olsson L, Chanock SJ. Common genetic variants in miR-1206 (8q24.2) and miR-612 (11q13.3) affect biogenesis of mature miRNA forms. PLoS One. 2012;7:e47454.PubMedPubMedCentralCrossRef
15.
Neilsen CT, Goodall GJ, Bracken CP. IsomiRs--the overlooked repertoire in the dynamic microRNAome. Trends Genet. 2012;28:544–9.PubMedCrossRef
16.
17.
Bolon B. Cellular and molecular mechanisms of autoimmune disease. Toxicol Pathol. 2012;40:216–29.PubMedCrossRef
18.
Lee UJ, Choung SR, Prakash KV, Lee EJ, Lee MY, Kim YJ, et al. Dual knockdown of p65 and p50 subunits of NF-kappaB by siRNA inhibits the induction of inflammatory cytokines and significantly enhance apoptosis in human primary synoviocytes treated with tumor necrosis factor-alpha. Mol Biol Rep. 2008;35:291–8.PubMedCrossRef
19.
Deighton CM, Walker DJ, Griffiths ID, Roberts DF. The contribution of HLA to rheumatoid arthritis. Clin Genet. 1989;36:178–82.PubMedCrossRef
20.
Chung IM, Ketharnathan S, Thiruvengadam M, Rajakumar G. Rheumatoid arthritis: the stride from research to clinical practice. Int J Mol Sci. 2016;17:1–10.
21.
22.
Karlson EW, Chibnik LB, Kraft P, Cui J, Keenan BT, Ding B, et al. Cumulative association of 22 genetic variants with seropositive rheumatoid arthritis risk. Ann Rheum Dis. 2010;69:1077–85.PubMedPubMedCentralCrossRef
23.
24.
Yang B, Chen J, Li Y, Zhang J, Li D, Huang Z, et al. Association of polymorphisms in pre-miRNA with inflammatory biomarkers in rheumatoid arthritis in the Chinese Han population. Hum Immunol. 2012;73:101–6.PubMedCrossRef
25.
Xu Z, Zhang E, Duan W, Sun C, Bai S, Tan X. The association between miR-499 polymorphism and cancer susceptibility: a meta-analysis. Onco Targets Ther. 2015;8:2179–86.PubMedPubMedCentralCrossRef
26.
Hashemi M, Eskandari-Nasab E, Zakeri Z, Atabaki M, Bahari G, Jahantigh M, et al. Association of pre-miRNA-146a rs2910164 and pre-miRNA-499 rs3746444 polymorphisms and susceptibility to rheumatoid arthritis. Mol Med Rep. 2013;7:287–91.PubMed
27.
El-Shal AS, Aly NM, Galil SM, Moustafa MA, Kandel WA. Association of microRNAs genes polymorphisms with rheumatoid arthritis in Egyptian female patients. Joint BoneSpine. 2013;80:626–31.
28.
Toraih EA, Ismail NM, Toraih AA, Hussein MH, Fawzy MS. Precursor miR-499a variant but not miR-196a2 is associated with rheumatoid arthritis susceptibility in an Egyptian population. Mol Diagn Ther. 2016;20:279–95.PubMedCrossRef
29.
Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther. 2008;10:R101.PubMedPubMedCentralCrossRef
30.
Stanczyk J, Pedrioli DM, Brentano F, Sanchez-Pernaute O, Kolling C, Gay RE, et al. Altered expression of microRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 2008;58:1001–9.PubMedCrossRef
31.
Duroux-Richard I, Jorgensen C, Apparailly F. miRNAs and rheumatoid arthritis—promising novel biomarkers. Swiss Med Wkly. 2011;141:w13175.PubMed
32.
Xu B, Feng NH, Li PC, Tao J, Wu D, Zhang ZD, et al. A functional polymorphism in pre-miR-146a gene is associated with prostate cancer risk and mature miR-146a expression in vivo. Prostate. 2010;70:467–72.PubMedCrossRef
33.
Zhou X, Zhu J, Zhang H, Zhou G, Huang Y, Liu R. Is the microRNA-146a (rs2910164) polymorphism associated with rheumatoid arthritis? Association of microRNA-146a (rs2910164) polymorphism and rheumatoid arthritis could depend on gender. Joint Bone Spine. 2015;82:166–71.PubMedCrossRef
34.
Jiménez-Morales S, Gamboa-Becerra R, Baca V, Del Río-Navarro BE, López-Ley DY, Velázquez-Cruz R, et al. MiR-146a polymorphism is associated with asthma but not with systemic lupus erythematosus and juvenile rheumatoid arthritis in Mexican patients. Tissue Antigens. 2012;80:317–21.PubMedCrossRef
35.
Chatzikyriakidou A, Voulgari PV, Georgiou I, Drosos AA. A polymorphism in the 3′-UTR of interleukin-1 receptor-associated kinase (IRAK1), a target gene of miR-146a, is associated with rheumatoid arthritis susceptibility. Joint Bone Spine. 2010;77:411–3.PubMedCrossRef
36.
Singh S, Rai G, Aggarwal A. Association of microRNA-146a and its target gene IRAK1 polymorphism with enthesitis related arthritis category of juvenile idiopathic arthritis. Rheumatol Int. 2014;34:1395–400.PubMedCrossRef
37.
38.
Cui Y, Sheng Y, Zhang XJ. Genetic susceptibility to SLE: recent progress from GWAS. Autoimmunity. 2013;41:25–33.CrossRef
39.
Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y, et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 2009;60:1065–75.PubMedCrossRef
40.
Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2008;105:7269–74.PubMedPubMedCentralCrossRef
41.
Löfgren SE, Frostegård J, Truedsson L, Pons-Estel BA, D'Alfonso S, Witte T, et al. Genetic association of miRNA-146a with systemic lupus erythematosus in Europeans through decreased expression of the gene. Genes Immun. 2012;13:268–74.PubMedPubMedCentralCrossRef
42.
Zhang J, Yang B, Ying B, Li D, Shi Y, Song X, et al. Association of pre-microRNAs genetic variants with susceptibility in systemic lupus erythematosus. Mol Biol Rep. 2011 Mar;38(3):1463–8.PubMedCrossRef
43.
Ciccacci C, Perricone C, Ceccarelli F, Rufini S, Di Fusco D, Alessandri C, et al. A multilocus genetic study in a cohort of Italian SLE patients confirms the association with STAT4 gene and describes a new association with HCP5 gene. PLoS One. 2014;9:e111991.PubMedPubMedCentralCrossRef
44.
Harley JB, Alarcon-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet. 2008;40:204–10.PubMedPubMedCentralCrossRef
45.
Sheng YJ, Xu JH, Wu YG, Zuo XB, Gao JP, Lin Y, et al. Association analyses confirm five susceptibility loci for systemic lupus erythematosus in the Han Chinese population. Arthritis Res Ther. 2015;17:85.PubMedPubMedCentralCrossRef
46.
Tang ZM, Wang P, Chang PP, Hasahya T, Xing H, Wang JP, et al. Association between rs2431697 T allele on 5q33.3 and systemic lupus erythematosus: case-control study and meta-analysis. Clin Rheumatol. 2015;34:1893–902.PubMedPubMedCentralCrossRef
47.
Luo X, Yang W, Ye DQ, Cui H, Zhang Y, Hirankarn N, et al. A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. PLoS Genet. 2011;7:e1002128.PubMedPubMedCentralCrossRef
48.
Leng RX, Wang W, Cen H, Zhou M, Feng CC, Zhu Y, et al. Gene-gene and gene-sex epistatic interactions of MiR146a, IRF5, IKZF1, ETS1 and IL21 in systemic lupus erythematosus. PLoS One. 2012;7:e51090.PubMedPubMedCentralCrossRef
49.
50.
51.
Wu F, Zikusoka M, Trindade A, Dassopoulos T, Harris ML, Bayless TM, et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology. 2008;135:1624–35.PubMedCrossRef
52.
Takagi T, Naito Y, Mizushima K, Hirata I, Yagi N, Tomatsuri N, et al. Increased expression of microRNA in the inflamed colonic mucosa of patients with active ulcerative colitis. J Gastroenterol Hepatol. 2010;25(Suppl 1):S129–33.PubMedCrossRef
53.
Fasseu M, Tréton X, Guichard C, Pedruzzi E, Cazals-Hatem D, Richard C, et al. Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PLoS One. 2010;5:e13160.PubMedPubMedCentralCrossRef
54.
Hoffman AE, Zheng T, Yi C, Leaderer D, Weidhaas J, Slack F, et al. MicroRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. Cancer Res. 2009;69:5970–7.PubMedPubMedCentralCrossRef
55.
Okubo M, Tahara T, Shibata T, Yamashita H, Nakamura M, Yoshioka D, et al. Association study of common genetic variants in pre-microRNAs in patients with ulcerative colitis. J Clin Immunol. 2011;31:69–73.PubMedCrossRef
56.
Ciccacci C, Politi C, Biancone L, Latini A, Novelli G, Calabrese E, et al. Polymorphisms in MIR122, MIR196A2, and MIR124A genes are associated with clinical phenotypes in inflammatory bowel diseases. Mol Diagn Ther. 2017;21:107–14.PubMedCrossRef
57.
Gazouli M, Papaconstantinou I, Stamatis K, Vaiopoulou A, Zeglinas C, Vassiliou I, et al. Association study of genetic variants in miRNAs in patients with inflammatory bowel disease: preliminary results. Dig Dis Sci. 2013;58:2324–8.PubMedCrossRef
58.
Chen Y, Wang C, Liu Y, Tang L, Zheng M, Xu C, et al. miR-122 targets NOD2 to decrease intestinal epithelial cell injury in Crohn’s disease. Biochem Biophys Res Commun. 2013;438:133–9.PubMedCrossRef
59.
Fattahi S, Alivije MK, Babamahmoodi F, Bayani M, Sadeghi-Haddad-Zavareh M, Asouri M, et al. Impact of genetic variants in Mir-122 gene and its flanking regions on hepatitis B risk. Int Biol Biomed J. 2017;3:1–7.
60.
Koukos G, Polytarchou C, Kaplan JL, Oikonomopoulos A, Ziring D, Hommes DW, et al. A microRNA signature in pediatric ulcerative colitis: deregulation of the miR-4284/CXCL5 pathway in the intestinal epithelium. Inflamm Bowel Dis. 2015;21:996–1005.PubMedPubMedCentralCrossRef
61.
Qi L, Hu Y, Zhan Y, Wang J, Wang BB, Xia HF, et al. A SNP site in pri-miR-124 changes mature miR-124 expression but no contribution to Alzheimer's disease in a Mongolian population. Neurosci Lett. 2012;15:1–6.CrossRef
62.
Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343:938–52.PubMedCrossRef
63.
Racosta JM, Kimpinski K, Morrow SA, Kremenchutzky M. Autonomic dysfunction in 355 multiple sclerosis. Auton Neurosci. 2015;193:1–6.PubMedCrossRef
64.
Iwanowski P, Losy J. Immunological differences between classical phenothypes of multiple sclerosis. J Neurol Sci. 2015;349:10–4.
65.
66.
Oksenberg JR. Decoding multiple sclerosis: an update on genomics and future directions. Expert Rev Neurother. 2013;13:11–9.PubMedCrossRef
67.
Haghikia A, Haghikia A, Hellwig K, Baraniskin A, Holzmann A, Decard BF, et al. Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study. Neurology. 2012;79:2166–70.PubMedCrossRef
68.
Keller A, Leidinger P, Lange J, Borries A, Schroers H, Scheffler M, et al. Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PLoS One. 2009;4:e7440.PubMedPubMedCentralCrossRef
69.
Lindberg RLP, Hoffmann F, Kuhle J, Kappos L. Circulating microRNAs as indicators for disease course of multiple sclerosis. Mult Scler. 2010;16:S41–S196.
70.
Junker A, Krumbholz M, Eisele S, Mohan H, Augstein F, Bittner R, et al. Microrna profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain. 2009;132:3342–52.PubMedCrossRef
71.
Fenoglio C, Cantoni C, De Riz M, Ridolfi E, Cortini F, Serpente M, et al. Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis. Neurosci Lett. 2011;504:9–12.PubMedCrossRef
72.
Li Y, Du C, Wang W, Ma G, Cui L, Zhou H, et al. Genetic association of MiR-146a with multiple sclerosis susceptibility in the Chinese population. Cell Physiol Biochem. 2015;35:281–91.PubMedCrossRef
73.
Kiselev I, Bashinskaya V, Kulakova O, Baulina N, Popova E, Boyko A, et al. Variants of microRNA genes: gender-specific associations with multiple sclerosis risk and severity. Int J Mol Sci. 2015;16:20067–81.PubMedPubMedCentralCrossRef
74.
Vogt L, Schmitz N, Kurrer MO, Bauer M, Hinton HI, Behnke S, et al. VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J Clin Invest. 2006;116:2817–26.PubMedPubMedCentralCrossRef
75.
Ridolfi E, Fenoglio C, Cantoni C, Calvi A, De Riz M, Pietroboni A, et al. Expression and genetic analysis of microRNAs involved in multiple sclerosis. Int J Mol Sci. 2013;14:4375–84.PubMedPubMedCentralCrossRef
76.
Fenoglio C, Ridolfi E, Cantoni C, De Riz M, Pietroboni A, Serpente M, et al. Decreased circulating miRNAs in patients with multiple sclerosis. Mult Scler J. 2011;18(S4):255–77.
77.
Paraboschi EM, Soldà G, Gemmati D, Orioli E, Zeri G, Benedetti MD, et al. Genetic association and altered gene expression of mir-155 in multiple sclerosis patients. Int J Mol Sci. 2011;12:8695–712.PubMedPubMedCentralCrossRef
78.
Smith JR, Rosenbaum JT. Management of uveitis: a rheumatologic perspective. Arthritis Rheum. 2002;46:309–18.PubMedCrossRef
79.
Yang P, Fang W, Meng Q, Ren Y, Xing L, Kijlstra A. Clinical features of Chinese patients with Behcet’s disease. Ophthalmology. 2008;115:312–8.PubMedCrossRef
80.
Yang P, Ren Y, Li B, Fang W, Meng Q, Kijlstra A. Clinical characteristics of Vogt–Koyanagi–Harada syndrome in Chinese patients. Ophthalmology. 2007;114:606–14.PubMedCrossRef
81.
Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet’s disease susceptibility loci. Nat Genet. 2010;42:703–6.PubMedCrossRef
82.
Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet’s disease. Nat Genet. 2010;42:698–702.PubMedPubMedCentralCrossRef
83.
Du L, Yang P, Hou S, Lin X, Zhou H, Huang X, et al. Association of the CTLA-4 gene with Vogt–Koyanagi–Harada syndrome. Clin Immunol. 2008;127:43–8.PubMedCrossRef
84.
Stittrich AB, Haftmann C, Sgouroudis E, Kuhl AA, Hegazy AN, Panse I, et al. The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated helper T lymphocytes. Nat Immunol. 2010;11:1057–62.PubMedCrossRef
85.
Kerdiles YM, Stone EL, Beisner DR, McGargill MA, Ch'en IL, Stockmann C, et al. Foxo transcription factors control regulatory Tcell development and function. Immunity. 2010;33:890–904.PubMedPubMedCentralCrossRef
86.
87.
Yu H, Liu Y, Bai L, Kijlstra A, Yang P. Predisposition to Behçet’s disease and VKH syndrome by genetic variants of miR-182. J Mol Med (Berl). 2014;92:961–7.CrossRef
88.
Zhou Q, Hou S, Liang L, Li X, Tan X, Wei L, et al. MicroRNA-146a and Ets-1 gene polymorphisms in ocular Behcet’s disease and Vogt-Koyanagi-Harada syndrome. Ann Rheum Dis. 2014;73:170–6.PubMedCrossRef
89.
Oner T, Yenmis G, Tombulturk K, Cam C, Kucuk OS, Yakicier MC, et al. Association of pre-miRNA-499 rs3746444 and pre-miRNA-146a rs2910164 polymorphisms and susceptibility to Behcet’s disease. Genet Test Mol Biomarkers. 2015;19:424–30.PubMedCrossRef
90.
Qi J, Hou S, Zhang Q, Liao D, Wei L, Fang J, et al. A functional variant of pre-miRNA-196a2 confers risk for Behcet’s disease but not for Vogt-Koyanagi-Harada syndrome or AAU in ankylosing spondylitis. Genet. 2013;132:1395–404.
91.
Sun J, Hoshino H, Takaku K, Nakajima O, Muto A, Suzuki H, et al. Bach1 regulates enhancer availability of heme oxygenase-1 gene. EMBO J. 2002;21:5216–24.PubMedPubMedCentralCrossRef
92.
Paine A, Eiz-Vesper B, Blasczyk R, Immenschuh S. Signaling to heme oxygenase-1 and its anti-inflammatory therapeutic potential. Biochem Pharmacol. 2010;80:1895–903.PubMedCrossRef
93.
94.
Castro-Santos P, Gutiérrez MA, Díaz-Peña R. Genetics of ankylosing spondylitis. Rev med Chil. 2014;142:1165–73.
95.
Xu HY, Wang ZY, Chen JF, Wang TY, Wang LL, Tang LL, et al. Association between ankylosing spondylitis and the miR-146a and miR-499 polymorphisms. PLoS One. 2015;10:e0122055.PubMedPubMedCentralCrossRef
96.
Niu Z, Wang J, Zou H, Yang C, Huang W, Jin L. Common MIR146A polymorphisms in Chinese ankylosing spondylitis subjects and controls. PLoS One. 2015;10:e0137770.PubMedPubMedCentralCrossRef
97.
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–85.PubMedCrossRef
98.
Murphy M, Kerr P, Grant-Kels JM. The histopathologic spectrum of psoriasis. Clin Dermatol. 2007;25:524–8.PubMedCrossRef
99.
100.
101.
102.
103.
Zhang W, Yi X, Guo S, Shi Q, Wei C, Li X, et al. A single-nucleotide polymorphism of miR-146a and psoriasis: an association and functional study. J Cell Mol Med. 2014;18:2225–34.PubMedPubMedCentralCrossRef
104.
Srivastava A, Nikamo P, Lohcharoenkal W, Li D, Meisgen F, Landén NX, et al. MicroRNA-146a suppresses IL-17-mediated skin inflammation and is genetically associated with psoriasis. J Allergy Clin Immunol. 2016; doi:10.​1016/​j.​jaci.​2016.​07.​025.
105.
Chatzikyriakidou A, Voulgari PV, Georgiou I, Drosos AA. The role of microRNA-146a (miR-146a) and its target IL-1R-associated kinase (IRAK1) in psoriatic arthritis susceptibility. Scand J Immunol. 2010;71:382–5.PubMedCrossRef
106.
Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;21:2095–6.
107.
108.
109.
Bernecker C, Lenz L, Ostapczuk MS, Schinner S, Willenberg H, Ehlers M, et al. MicroRNAs miR-146a1, miR-155-2, and miR-200a1 are regulated in autoimmune thyroid diseases. Thyroid. 2012;22:1294–5.PubMedCrossRef
110.
Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang D, Aguiar RC. MicroRNAs miR-125a and miR-125b constitutively activate the NF-kappaB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci U S A. 2012;109:7865–70.PubMedPubMedCentralCrossRef
111.
Inoue Y, Watanabe M, Inoue N, Kagawa T, Shibutani S, Otsu H, et al. Associations of single nucleotide polymorphisms in precursor-microRNA (miR)-125a and the expression of mature miR-125a with the development and prognosis of autoimmune thyroid diseases. Clin Exp Immunol. 2014;178:229–35.PubMedPubMedCentralCrossRef
112.
Duan R, Pak C, Jin P. Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Hum Mol Genet. 2007;16:1124–31.PubMedCrossRef
113.
Cai T, Li J, An X, Yan N, Li D, Jiang Y, et al. Polymorphisms in MIR499A and MIR125A gene are associated with autoimmune thyroid diseases. Mol Cell Endocrinol. 2016;440:106–15.PubMedCrossRef
114.
115.
Luo Y, Wang Y, Wang Q, Xiao R, Lu Q. Systemic sclerosis: genetics and epigenetics. J Autoimmun. 2013;41:161–7.PubMedCrossRef
116.
117.
Li H, Yang R, Fan X, Gu T, Zhao Z, Chang D, et al. MicroRNA array analysis of microRNAs related to systemic scleroderma. Rheumatol Int. 2012;32:307–13.PubMedCrossRef
118.
Sakoguchi A, Jinnin M, Makino T, Kajihara I, Makino K, Honda N, et al. The miR- 146a rs2910164 C/G polymorphism is associated with telangiectasia in systemic sclerosis. Clin Exp Dermatol. 2013;38:99–100.PubMedCrossRef
119.
Sontheimer RD. Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. Curr Opin Rheumatol. 1999;11:475–82.PubMedCrossRef
120.
Okada Y, Jinnin M, Makino T, Kajihara I, Makino K, Honda N, et al. MIRSNP rs2910164 of miR-146a is associated with the muscle involvement in polymyositis/dermatomyositis. Int J Dermatol. 2014;53:300–4.PubMedCrossRef
121.
Eisenberg I, Eran A, Nishino I, Moggio M, Lamperti C, Amato AA, et al. Distinctive patterns of microRNA expression in primary muscular disorders. Proc Natl Acad Sci U S A. 2007;104:17016–21.PubMedPubMedCentralCrossRef
Metadata
Title
Polymorphisms in miRNA genes and their involvement in autoimmune diseases susceptibility
Authors
Andrea Latini
Cinzia Ciccacci
Giuseppe Novelli
Paola Borgiani
Publication date
01-08-2017
Publisher
Springer US
Published in
Immunologic Research / Issue 4/2017
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-017-8937-8

Other articles of this Issue 4/2017

Immunologic Research 4/2017 Go to the issue

Original Article

Neuroprotective effects of G-CSF administration in microglia-mediated reactive T cell activation in vitro

Original Article

The levels of DNGR-1 and its ligand-bearing cells were altered after human and simian immunodeficiency virus infection

Review

Dendritic cell-based immunotherapy: a basic review and recent advances

Original Article

Vitamin D inhibits the Staphylococcal enterotoxin B-induced expression of tumor necrosis factor in microglial cells

Original Article

Thymus vulgaris L. and thymol assist murine macrophages (RAW 264.7) in the control of in vitro infections by Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans

Original Article

Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer